Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents

Withdrawn before enrolling · Phase 4

Conditions studied: Coronary Artery Disease

In brief

It is recommended that patients who have drug-eluting stents placed in their coronary arteries take aspirin and Plavix (Clopidogrel) for at least a year. Patients who stop taking these antiplatelet drugs or who have resistance to the antiplatelet effects of these drugs are at a higher risk of clots occurring inside the stents which may result in a heart attack. At the present time, it is unknown if increasing the doses of the antiplatelet agents is effective in overcoming this resistance. The purpose of this project is to identify patients with antiplatelet drug resistance and to test whether an increase in the Plavix (Clopidogrel) dose overcomes antiplatelet drug resistance.

Key facts

Study ID

NCT00589862

Run by

Creighton University

People needed

0

Starts

2007-10-01

Expected to finish

2008-07-01

Last updated by the study team

2015-11-30

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Required Coronary Artery Angioplasty with a drug-eluting stent deployment

You may not qualify if…

• The last drug-eluting stent placed greater than 2 weeks prior
• Aspirin or Plavix (Clopidogrel) allergy or contraindication

Where it is running

• Creighton University Medical Center — Omaha, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.